posted on 2016-04-12, 00:00authored byAmaia Artal-Martinez de Narvajas, Timothy S. Gomez, Jin-San Zhang, Alexander O. Mann, Yoshiyuki Taoda, Jacquelyn A. Gorman, Marta Herreros-Villanueva, Thomas M. Gress, Volker Ellenrieder, Luis Bujanda, Do-Hyung Kim, Alan P. Kozikowski, Alexander Koenig, Daniel D. Billadeau
Macroautophagy is an evolutionarily conserved cellular process involved in the clearance of proteins and organelles. Although the cytoplasmic machinery that orchestrates autophagy induction during starvation, hypoxia, or receptor stimulation has been widely studied, the key epigenetic events that initiate and maintain the autophagy process remain unknown. Here we show that the methyltransferase G9a coordinates the transcriptional activation of key regulators of autophagosome formation by remodeling the chromatin landscape. Pharmacological inhibition or RNA interference (RNAi)-mediated suppression of G9a induces LC3B expression and lipidation that is dependent on RNA synthesis, protein translation, and the methyltransferase activity of G9a. Under normal conditions, G9a associates with the LC3B, WIPI1, and DOR gene promoters, epigenetically repressing them. However, G9a and G9a-repressive histone marks are removed during starvation and receptor-stimulated activation of naive T cells, two physiological inducers of macroautophagy. Moreover, we show that the c-Jun N-terminal kinase (JNK) pathway is involved in the regulation of autophagy gene expression during naive-T-cell activation. Together, these findings reveal that G9a directly represses genes known to participate in the autophagic process and that inhibition of G9a-mediated epigenetic repression represents an important regulatory mechanism during autophagy.
Funding
This study was supported in part by the Mayo Foundation for Medical Research. D.D.B. was supported by NCI-funded Pancreatic Cancer SPORE grant CA102701. A.K. was supported by a Mildred-Scheel fellowship of the Deutsche Krebshilfe (no. 109294). M.H.V. was supported by Universidad del Pais Vasco, Instituto Biodonostia, San Sebastian, Spain, and CIBERehd (red de enfermedades hepaticas y digestivas). V.E. was supported by Deutsche Forschungsgemeinschaft (KF0210, SFB-TR17, and German Cancer Research Foundation no. 109423). NIGMS GM097057 was awarded to D.H.K.